GOLDCOAST RESOURCE CORP. (formerly “Psyence Group Inc.”)

Unaudited Condensed Consolidated Interim Financial Statements

For the three months ended June 30, 2026

Expressed in Canadian Dollars

(CAD $)

NOTICE OF NO AUDITOR REVIEW OF CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

Under National Instrument 51-102 if an auditor has not performed a review of the interim financial statements, they must be accompanied by a notice indicating that the financial statements have not been reviewed by an auditor.

The accompanying unaudited condensed consolidated interim financial statements of Goldcoast Resource Corp. (formerly “Psyence Group Inc.”) (“the Company”) have been prepared by and are the responsibility of the Company’s management.

The Company’s independent auditor has not performed a review of these financial statements in accordance with standards established by the Canadian Institute of Chartered Accountants for a review of interim financial statements by an entity’s auditor.

(Expressed in Canadian Dollars)

Unaudited Condensed Consolidated Interim Statements of Financial Position

As at June 30, 2026 and March 31, 2026

CAD $	Note	As at June 30, 2026	As at March 31, 2026
ASSETS			
Current assets			
Cash and cash equivalents	5	343,972	439,941
Other receivables	6	10,093	6,872
Prepaids		-	5,739
Loan receivable from former GoldCoast Resources Corp.	7	372,960	364,238
Total current assets		727,025	816,790
TOTAL ASSETS		**727,025**	**816,790**
LIABILITIES			
Current liabilities			
Accounts payable and accrued liabilities	9	133,019	137,237
Total current liabilities		133,019	137,237
TOTAL LIABILITIES		**133,019**	**137,237**
SHAREHOLDERS' EQUITY			
Share capital	10	22,673,484,	22,537,858
Options reserve	10	1,832,785	1,954,090
Accumulated Deficit		(23,912,263)	(23,812,395)
TOTAL SHAREHOLDERS' EQUITY		**594,006**	**679,553**
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY		**727,025**	**816,790**

Nature of operations and going concern (note 1)
Subsequent events (note 17)

Approved on behalf of the Board of Directors.

"Tom Griffis"	"Michael Nikiforuk"
Executive Chairman and Director	Director

The accompanying notes are an integral part of the Unaudited Condensed Consolidated Interim Financial Statements.

(Expressed in Canadian Dollars)

Unaudited Condensed Consolidated Interim Statements of Net Loss and Comprehensive Loss

For three months ended June 30, 2026 and June 30, 2025

CAD $	Notes	2026	2025
Expenses			
Sales and marketing		858	117,714
Research and development		-	89,990
General and administrative		49,916	136,515
Professional fees and consulting fees		58,796	333,985
Depreciation and amortization		-	1,226
Loss before other items		**(109,569)**	**(679,430)**
Other items			
Interest income		9,793	-
Interest expense		-	(18,657)
Foreign exchange (loss)/gain		(92)	848
Loss on subsidiary disposal	11	-	(10,716,405)
Fair value loss on investment in Psyence Labs Ltd.	8	-	(219,441)
NET LOSS		**(99,868)**	**(11,633,085)**
Other comprehensive income/(loss)			
Foreign exchange (loss)/gain on translation		-	(737,522)
TOTAL COMPREHENSIVE LOSS		**(99,868)**	**(12,370,607)**
Net loss attributed to non-Controlling Interest	12	-	(636,862)
Net loss attributed to shareholders of the Company		(99,868)	(10,996,223)
Loss per share - basic and diluted		**(0.04)**	**(0.97)**
Weighted average number of outstanding shares - basic and diluted		**2,318,480**	**1,827,229**

The accompanying notes are an integral part of the Unaudited Condensed Consolidated Interim Financial Statements .

.

(Expressed in Canadian Dollars)

Unaudited Condensed Consolidated Interim Statements of Changes in Shareholders' Equity

For three months ended June 30, 2026 and June 30, 2025

	Note	Number of shares	Share capital ($)	Options reserve ($)	Foreign currency translation reserve ($)	Deficit ($)	Non-controlling interest ($)	Total shareholders' equity/(deficit) ($)
Opening balance as at April 1, 2025		1,349,485	21,826,722	1,949,797	737,522	(23,226,817)	8,253,894	9,541,118
Share based compensation	10			90,831				90,831
Exercise of RSU's	10	36,020	157,513	(157,513)	-	-	-	-
Shares issued for cash, net of issuance costs		688,565	479,000	-	-	-	-	479,000
Disposal of Subsidiaries	11	-	-	-	-	10,577,547	(7,700,652)	2,876,895
Noncontrolling interest adjustment for change in ownership	12	-	-	-	-	-	83,621	83,621
Other comprehensive loss		-	-	-	(737,522)	-	-	(737.522)
Net loss		-	-	-		(10,996,223)	(636,862)	(11,633,086)
Balance, June 30, 2025		**2,074,070**	**22,463,235**	**1,883,115**	**-**	**(23,645,493)**	**-**	**700,857**
Opening balance as at April 1, 2026		2,247,879	22,537,858	1,954,090	-	(23,812,395)	-	679,553
Share based compensation	10			14,321	-	-	-	14,321
Exercise of RSU's	10	70,601	135,626	(135,626)	-	-	-	
Net loss		**-**	**-**	**-**	**-**	**(99,868)**	**-**	**(99,868)**
Balance, June 30, 2026		**2,318,480**	**22,673,484**	**1,832,785**	**-**	**(23,912,263)**	**-**	**594,006**

The accompanying notes are an integral part of the Unaudited Condensed Consolidated Interim Financial Statements

(Expressed in Canadian Dollars)

Unaudited Condensed Consolidated Interim Statements of Cash Flows

For three months ended June 30, 2026 and June 30, 2025

	Note	June 30, 2026	June 30, 2025
Net loss		(99,868)	(11,633,085)
Non-cash adjustments:			
Depreciation and amortization		-	1,226
Foreign exchange		-	110,307
Share issuance to third party advisors		-	83,621
Share based compensation	10	14,321	90,831
Loss on disposal of subsidiaries	11	-	10,716,405
Fair value loss on investment	8	-	219,441
Changes in working capital:			
Other receivables		(3,221)	32,433
Prepaids		5,738	48,180
Accounts payable and accrued liabilities		(4,218)	(124,264)
Cash used in operating activities		**(95,969)**	**(454,905)**
Loss on disposal of subsidiaries	11	-	(7,763,528)
Investment in Psyence Labs Ltd	8	-	(345,300)
Cash used in investing activities		**-**	**(8,108,828)**
Proceeds from shares disposal		-	479,000
Cash provided from financing activities		**-**	**479,000**
Change in cash and cash equivalents		(95,969)	(8,084,733)
Cash and cash equivalents, beginning of period		439,941	8,888,570
Cash and cash equivalents, end of period		**343,972**	**803,837**

The accompanying notes are an integral part of the Unaudited Condensed Consolidated Interim Financial Statements

Notes to the Consolidated Financial Statements

1. Nature of operations and going concern

Psyence Group Inc. (the **"Company"** or **"PGI"**) was a life science biotechnology company focused on the research, cultivation and production of psychedelics and nature-based compounds to treat psychological trauma in the context of palliative care and in support of mental wellness. The safety and efficacy of psychedelics would be evaluated through rigorous clinical trials.

The Company's registered office was at 121 Richmond Street West, Penthouse Suite, 1300, Toronto, Ontario M5H 2K1. The Company commenced trading on the Canadian Securities Exchange (**"CSE"**) on January 27, 2021 under the symbol "PSYG".

On August 20, 2025, the Company entered into the letter of intent (the "LOI") with GoldCoast Resource Corp. ("GoldCoast") to acquire all of the issued and outstanding securities and securities convertible into securities of GoldCoast, a corporation existing under the laws of Ontario.

On November 21, 2025, the Company, GoldCoast and Psyence Therapeutics Corp., a wholly owned subsidiary of the Company, entered into a definitive amalgamation agreement (the "Agreement") which superseded the LOI.

Under the terms of the Agreement, the Company, GoldCoast and Psyence Therapeutics Corp. agreed to structure the business combination by way of an amalgamation of GoldCoast and Psyence Therapeutics Corp. (the "Amalgamation") in accordance with the Business Corporation Act (Ontario) (the "OBCA").

Under the terms of the Agreement, the Company would complete a name change to GoldCoast Resource Corp. (or such other name as may be approved by GoldCoast and applicable regulatory authorities) and a share consolidation prior to closing of the business combination.

At the effective time of the Amalgamation between GoldCoast and Psyence Therapeutics Corp., the following shall occur in the following order:

Psyence Therapeutics Corp. and GoldCoast shall amalgamate to form Amalco and shall continue as one company under the OBCA and with the effect set out in Section 179 of the OBCA. Amalco will become a wholly owned subsidiary of the Resulting Issuer (the Company after giving effect to the Amalgamation).

Immediately upon the Amalgamation:

- Each one GoldCoast share shall be exchanged for one fully paid and non-assessable Resulting Issuer shares;
- Each Psyence Therapeutics Corp. share shall be exchanged for one fully paid and non-assessable Amalco share;
- Each holder of one option granted pursuant to the GoldCoast Option Plan outstanding immediately before the Amalgamation shall be exchanged for one Resulting Issuer Option having the same economic terms as the option for which it is being exchanged.

With respect to each GoldCoast share, exchanged in accordance with provisions detailed above:

- The holders thereof shall cease to be the holders of such GoldCoast shares, as the case may be, and the name of each such holder shall be removed from the applicable register of holders of such GoldCoast securities;
- The GoldCoast securities as noted above shall be deemed to have been cancelled as of the effective date of the Amalgamation.

On the effective date of the Amalgamation:

- GoldCoast and Psyence Therapeutics Corp. shall amalgamate and continue as Amalco under the terms and conditions prescribed in the Agreement;
- GoldCoast and Psyence Therapeutics Corp. shall cease to exist as entities separate from Amalco;

- Amalco shall possess all the property, rights, privileges and franchises and is subject to all liabilities, including civil, criminal and quasi-criminal, and all contracts, disabilities and debts of each of GoldCoast and Psyence Therapeutics Corp.;
- A conviction against, or ruling, order or judgment in favour or against either GoldCoast and Psyence Therapeutics Corp. may be enforced by or against Amalco;
- The Articles of Amalgamation are deemed to be the articles of incorporation of Amalco;
- Amalco shall be deemed to be the party plaintiff or the party defendant, as the case may be, in any civil action commenced by or against an amalgamating corporation before the Amalgamation has become effective;
- The initial directors of Amalco shall be the same directors as the Resulting Issuer; and
- The initial management of Amalco shall be the same management as the Resulting Issuer.

The closing of the business combination is subject to customary conditions in accordance with the Agreement including but not limited to regulatory approvals and the Company having a minimum cash balance of $400,000 and no liabilities at the date of the closing.

The Agreement can be terminated by the Company or GoldCoast if conditions precedent detailed in the Agreement were not met.

On January 27, 2026 the Company announced that GoldCoast has been granted a series of ten contiguous offshore licenses in accordance with Section 31 of the Minerals and Mining Act, 2006 (Act 703) by the Minerals Commission of Ghana covering approximately 10,000 square kilometres area.

On February 24, 2026, the Company entered into an amending agreement (the "Amending Agreement") with GoldCoast and Psyence Therapeutics Corp, to amend the Agreement. The Amending Agreement provides for certain amendments to the Agreement in connection with the proposed Amalgamation, including: (i) an extension of the long-stop date for the holding of required shareholder meetings from January 30, 2026 to April 30, 2026; (ii) an extension of the outside date for completion of the Amalgamation (the "Closing Date") from March 31, 2026 to May 31, 2026; (iii) a corresponding extension of the termination date under the Agreement from March 31, 2026 to May 31, 2026; and (iv) a reduction of the minimum cash condition applicable to the Company at closing from $400,000 to $250,000.

On July 20, 2026, the Company entered an amendment with GoldCoast and Psyence Therapeutics Corp, to the previously announced amalgamation agreement dated November 21, 2025. The Amendment accounts for the replacing the closing date by deleting "May 31, 2026" with "July 31, 2026".

On July 27, 2026, the transaction with Goldcoast has closed (see Note 17) and the Company changed its name to Goldcoast Resource Corp. and its shares resume trading on the Canadian Securities Exchange under the symbol "GCR" from August 10, 2026.

On April 30, 2025 the Company sold all its shares in Psyence Biomedical Ltd. ("**PBM**"), its NASDAQ listed subsidiary which resulted in a loss of control over PBM, refer to Note 8.

On April 23, 2025, the Company consolidated its common shares and warrants on the basis of 15:1. On July 27, 2026 the Company consolidated its then outstanding 16,129,406 common shares into 2,318,480 common shares.

All prior share capital information has been presented based on these ratios.

Going concern

These consolidated financial statements have been prepared on a going concern basis which assumes that the Company will, in the foreseeable future, realize on its assets and discharge its liabilities in the normal course of business as they come due. Accordingly, the consolidated financial statements do not give effect to adjustments that would be necessary should the Company be unable to continue as a going concern and, therefore be required to realize its assets and liquidate its liabilities and commitments in other than the normal course of business and at amounts different from those in these consolidated financial statements.

As of June 30, 2026, the Company has an accumulated deficit of $23,912,263 (March 31, 2026- $23,812,395). In addition, the Company generated negative cash flow from operating activities of

$95,969 (2025- $454,905). Management has considered the significance of such condition in relation to the Company's ability to meet its current obligations and to achieve its business targets and determined that these conditions are indicators of material uncertainties that may cast significant doubt about the Company's ability to continue as a going concern.

The Company's ability to continue as a going concern is dependent upon its ability to generate future profitable operations and/or to obtain the necessary financing to conduct its planned business, meet its on-going levels of corporate overhead and discharge its liabilities as they come due. The Company has historically raised funds from the issuance of shares and convertible debentures. The Company's ability to obtain additional financing is materially uncertain, as there is no assurance that additional funding will be available on a timely basis or on terms acceptable to the Company.

2. Basis of presentation

Statement of compliance

These consolidated financial statements of the Company have been prepared in accordance with IFRS® Accounting Standards as issued by the International Accounting Standard Board ("IFRS") on a going concern basis. They were also prepared in accordance with IAS34, Interim Financial Reporting.

The consolidated financial statements were authorized for issuance on August 28 , 2026 by the directors of the Company.

Basis of measurement

These Consolidated Financial Statements have been prepared on a historical cost basis, except for certain financial instruments, which are classified as fair value through profit or loss ("**FVTPL**").

Functional and presentation currency

These consolidated financial statements are presented in Canadian Dollars (**"CAD $"),** which is also PGI's functional currency. The functional currency of PGI's subsidiaries: Psyence Therapeutics Corp ("**PTC"**) is Canadian Dollars; Psyence Australia (Pty) Ltd, is the Australian Dollar (**"AUD $"**); Psyence Biomedical Ltd, Psyence Biomed II Corp. and Newcourt Acquisition Corp., is the United States Dollar (**"USD $"**).

Basis of consolidation

These consolidated financial statements incorporate the accounts of the Company and its subsidiaries. A subsidiary is an entity controlled by the Company and its results are consolidated into the financial results of the Company from the effective date of control up to the effective date of loss of control.

Control exists when an investor is exposed, or has rights, to variable returns from the involvement with the investee and has liability to affect those returns through its power over the investee. Where the Company's interest is less than 100%, the Company recognizes non-controlling interests ("**NCI**").

The entities included in PGI consolidated financial statements as of June 30, 2026 are as follows:

Name of entity	Place of incorporation	% Ownership	Accounting method
Psyence Therapeutics Corp.	Ontario	100%	Consolidation

On April 30, 2025, the Company disposed fully of its interests in Psyence Biomedical Ltd, Psyence Biomed II Corp, Psyence Australia (Pty) Ltd and Newcourt Acquisition Corp. in exchange for fair value consideration of CAD$426,170.

3. Material accounting policies

The policies used for preparation of these unaudited condensed consolidated interim financial statements were the same accounting policies and methods of application as the audited consolidated financial statements of the Company for the year ended March 31, 2026 and were consistently applied to all the periods presented unless otherwise noted below. They do not include all of the information and disclosures required for annual financial statements. For further information, see the Company's audited consolidated financial statements for the year ended March 31, 2026.

4. Critical accounting estimates and judgements

The preparation of consolidated financial statements in conformity with IFRS requires management to make certain estimates, judgments and assumptions concerning the future. Actual results may differ from these estimates. The Company's management reviews these estimates, judgments, and assumptions on an ongoing basis, based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Revisions to estimates are adjusted prospectively in the period in which the estimates are revised. The following are considered to be critical accounting estimates and judgements by management for the period ended June 30, 2026 and June 30, 2025 as these require a high level of subjectivity and judgement and could have a material impact on the Company's consolidated financial statements.

Going concern

These Consolidated financial statements have been prepared on the assumption that the Company will continue as a going concern, meaning it will continue in operation for the foreseeable future and will be able to realize assets and discharge liabilities in the ordinary course of operations.

Management routinely plans future activities including forecasting future cash flows and forming judgements collectively with directors of the Company.

Judgement is required in determining if the Company's has sufficient cash reserves, together with all other available information, to continue as a going concern for a period of at least twelve months.

As at June 30, 2026 the Company has concluded that a material uncertainty exists that casts significant doubt about the Company's ability to continue as a going concern.

Contingencies

From time to time, the Company is named as a party to claims or involved in proceedings, including legal, regulatory and tax related, in the ordinary course of its business. While the outcome of these matters may not be estimable at the reporting date, the Company makes provisions, where possible, for the estimated outcome of such claims or proceedings. Should a loss result from the resolution of any claims or proceedings that differs from these estimates, the difference will be accounted for as a charge to profit or loss in that period. The actual results may vary and may cause significant adjustments.

The rebate over the tax claim is subject to inherent uncertainty and could be subject to being denied and clawed back by the Australian Tax office at a future date. The Company expects that a claw back of the rebate is highly unlikely.

Share-based compensation

The Company measures equity settled share-based payments based on their fair value at the grant date and recognize compensation expense over the vesting period based on management's estimate of equity instruments that will eventually vest. The determination of the fair value of stock options using the Black-Scholes option pricing model requires the input of highly subjective assumptions, including the expected price volatility. Changes in the subjective input assumptions could materially affect the fair value estimate. Expected forfeitures are estimated at the date of grant and subsequently adjusted if further information indicates actual forfeitures may vary from the original estimate. The impact of the revision of the original estimate is recognized in profit or loss such that the cumulative expense reflects the revised estimate.

For share-based payments granted to non-employees, the compensation expense is measured at the fair value of the goods and services received except where the fair value cannot be estimated in which case it is measured at the fair value of the equity instruments granted. The fair value of share-based compensation to non-employees is periodically re-measured until counterparty performance is complete, and any change therein is recognized over the period and in the same manner as if cash was paid instead of paying with or using equity instruments.

(Expressed in Canadian Dollars)

5. Cash and cash equivalents

Cash and cash equivalents include the following amounts:

- An amount of $343,972 unrestricted cash held with chartered banks.

6. Other receivables

Other receivables include the following amounts.

	June 30, 2026 $	March 31, 2026 $
Other receivables	119	119
Sales tax receivable	9,974	6,753
Total	**10,093**	**6,872**

7. Loan receivable from former GoldCoast Resources Corp.

On August 20, 2025, the Company signed a LOI with GoldCoast (Note 1) and agreed to advance $343,867 (US$250,000) subject to the terms and conditions of the Loan Agreement within 5 days of signing the LOI. Interest shall accrue on any outstanding amount at the rate of 10% per annum, payable upon maturity. During the period ended June 30, 2026, the Company recorded $8,721 (June 30, 2025 $nil) interest income in its consolidated financial statements of net loss and comprehensive loss. The loan will be secured pursuant to a general security agreement against all of the assets of GoldCoast. In the event that the Acquisition does not close, any amounts owing under the Loan shall be due and payable within 21 days of demand by the Company.

Subject to the terms and conditions of the LOI, if the amalgamation closes, the outstanding amount including all accrued and unpaid interest, shall be deemed satisfied and extinguished in full and shall no longer be repayable by GoldCoast. In consideration for such forgiveness, the Company shall receive an equity interest in the Resulting Issuer, as determined in accordance with the share conversion and exchange formula set out in the LOI which expressly accounts for the value of the outstanding amount being forgiven.

In the event that the amalgamation does not close by the earlier of (i) the closing date contemplates in the Definitive Agreement or (ii) July 31, 2026, the outstanding amount plus accrued interest shall be due and payable within 21 days of demand of the Company. If GoldCoast fails to pay the outstanding amount plus accrued interest by the due date, the Company shall have the right to convert the outstanding amount and accrued interest into that number of common shares of GoldCoast calculated at a price per share equal to the price of the last equity financing completed by GoldCoast prior to the date of the LOI, being US$0.057 per share.

8. Investment in Psyence Labs Ltd.

On April 28, 2025, the Company's former subsidiary PBM bought 250 PsyLabs shares in two tranches. The first tranche PBM bought 125 shares in exchange for $345,300 (US$250,000). The fair value loss of this investment was $219,441 (US$156,875), based on the arm's length subscription transaction by a third-party investor at US$745 per PsyLabs share.

The investment in PsyLabs was disposed on April 30, 2025 when the Company disposed its shares in PBM.

9. Accounts payable and accrued liabilities

Accounts payable and accrued liabilities include the following amounts:

(Expressed in Canadian Dollars)

	June 30, 2026 $	**March 31, 2026 $**
Trade payables	1,863	1,082
Provisions	131,155	136,155
Total	133,019	137,237

10. Share capital

Authorized share capital

Unlimited number of voting common shares without par value.

Issued and outstanding

Following the completion of the Reverse Takeover on July 27, 2026, a share consolidation of 1 share for every 6.9565 shares was affected. The number of shares in issues and weighted average number of shares for all periods presented have been retrospectively restated to reflect this consolidation.

As at June 30, 2026, there were 2,318,480 (June 30, 2025 – 2,074,070) issued and outstanding Common Shares.

Common shares	**2026**		**2025**	
	Number	**Amount ($)**	**Number**	**Amount ($)**
Opening balance April 1	2,247,879	22,463,235	1,349,485	21,826,722
Issuance of shares in private placement	-	-	688,565	479,000
Issuance of shares for RSUs exercise	70,601	135,626	36,020	157,513
Balance as at June 30,	2,318,609	22,673,484	2,074,070	22,463,235

Common shares

Private placements

On June 25, 2025 the Company issued 688,565 shares with a subscription price of $0.69 in a private placement. The Company received proceeds of $479,000.

RSU exercise

On June 12, 2025 the Company issued 36,020 shares for the exercise of RSU's by various consultants of the Company. Upon exercise, amounts totalling $157,513 was transferred from contributed surplus to share capital, determined by reference to the original fair value of the RSU's determined on the date of grant.

On April 21,2026 the Company issued 70,601 shares for the exercise of RSU's by various consultants of the Company. Upon exercise, amounts totalling $135,626 was transferred from contributed surplus to share capital, determined by reference to the original fair value of the RSU's determined on the date of grant.

Stock Options

The changes in stock options outstanding during the period ended June 30, 2026 and June 30, 2025 are as follows:

	Period ended June 30, 2026	
	Number of options	Weighted average exercise price ($)
Outstanding, at beginning of year	18,895	9.39
Options outstanding, ending	18,895	9.39
Options exercisable, ending	18,895	9.39

(Expressed in Canadian Dollars)

	Period ended June 30, 2025	
	Number of options	Weighted average exercise price ($)
Outstanding, at beginning of year	58,066	9.39
Options outstanding, ending	58,066	9.39
Options exercisable, ending	58,066	9.39

The following stock options are outstanding at June 30, 2026:

Expiry date	Number of options outstanding	Exercise price $	Weight average remaining life (years)	Number of options exercisable
December 31, 2027	3,993	2.78	1.50	3,993
March 31, 2028	13,465	14.61	1.75	13,465
May 25, 2028	1,438	14.61	1.90	1,438
	18,895		1.72	18,895

During the period ended June 30, 2026, $nil (June 30, 2025 - $nil) was expensed and recorded as share-based payments under professional fees and consulting fees and general and administrative in the consolidated statements of net loss and comprehensive loss based on the vesting terms and forfeiture of the options.

Restricted stock units (RSUs)

The changes in RSUs outstanding during the period ended June 30, 2026 and June 30, 2025 are as follows:

	Period ended June 30, 2026
	Number of RSUs
Outstanding, at beginning of the period	168,601
Exercised during the period	(70,601)
RSUs outstanding, ending	97,999
RSUs exercisable, ending	97,999

	Period ended June 30, 2025
	Number of RSUs
Outstanding, at beginning of the period	14,343
Issued during the period (i)(iii)(iv)	86,581
Exercised during the period	(36,032)
RSUs outstanding, ending	64,892
RSUs exercisable, ending	7,172

(i) On April 1, 2025, a total of 86,581 RSUs were issued to consultants of the Company.

The RSUs granted are accounted for as an equity instrument whereby share-based payments recognized in the consolidated statements of net loss and comprehensive loss are held in options reserve until exercised.

(Expressed in Canadian Dollars)

During the period ended June 30, 2026, $14,321 (June 30, 2025 - $90,831) was expensed and recorded as share-based payments under professional fees and consulting fees and general and administrative in the consolidated statements of net loss and comprehensive loss on the vesting of RSUs.

11. Disposal of PBM

On April 30, 2025, the Company sold all its ownership in PBM for the net proceeds of $426,170 to third party investors. As a result, the Company lost control over PBM. This resulted in the deconsolidation of PBM from the consolidated financial statements and the resulting loss on disposal has been recorded in the consolidated statements of net income (loss) and comprehensive income (loss).

The following summarizes the sale date fair value of the consideration received and the net book value of the assets sold and liabilities transferred:

Consideration received	426,170
Carrying value of NCI derecognised	7,445,938
Foreign currency translation reserve	562,371
Net assets disposed:	
Cash and cash equivalents	(7,813,202)
Other receivables	(156,437)
Prepaids	(313,801)
Property and equipment	(14,735)
Investment in Psyence Labs Ltd	(1,157,618)
Accounts payable and accrued liabilities	434,988
Derivative warrant liabilities	299,284
Loss on disposal	(287,042)

12. Non-controlling interest (NCI)

During the period ended June 30, 2026, the share of losses attributable to non-controlling shareholders was $0 (June 30, 2025 – of $636,862). On April 30, 2025, the Company sold all its ownership in PBM for the net proceeds of $426,170 to third party investors. As a result, the Company lost control over PBM. This resulted in the deconsolidation of PBM from the consolidated financial statements and the resulting loss on disposal of subsidiaries has been reflected in the consolidated statements of net loss and comprehensive income (loss). This resulted in the derecognition of NCI to the value of $7,445,938.

13. Transactions with related parties

All related party transactions are measured at the exchange amount, which is the amount of consideration established and agreed to by the related parties. All amounts either due from or due to related parties other than specifically disclosed are non-interest bearing, unsecured and have no fixed terms of repayments. The Company incurred the following transactions with related parties during the period ended June 30, 2026 and June 30, 2025:

Compensation to key management personnel

Key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the Company, directly or indirectly. Key management personnel include the Company's executive officers and Board of Directors.

Key Management Personnel	**June 30, 2026**	**June 30, 2025**
Short term benefits	3,627	44,296
Share-based compensation	9,860	70,713
Total	13,487	115,009

(Expressed in Canadian Dollars)

Short term benefits consist of consulting fees and other benefits paid to key management personnel.

Balances

As at June 30, 2026, the Company held amounts totalling $nil (June 30, 2025 - $nil) in accounts payable and accrued liabilities. These are amounts owing to key management personnel.

14. Financial instruments and financial risk management

In the normal course of business, the Company is exposed to a variety of financial risks: credit risk, liquidity risk, foreign exchange risk and interest rate risk. These financial risks are subject to normal credit standards, financial controls, risk management as well as monitoring. The Company's Board of Directors has overall responsibility for the establishment and oversight of the Company's risk management framework.

Credit risk

Credit risk arises from cash and cash equivalents, restricted cash, other receivables and loan to joint venture. The maximum exposure to credit risk is equal to the carrying value of the financial assets. The objective of managing counterparty credit risk is to prevent losses on financial assets. The Company minimizes the credit risk of cash by depositing with only reputable financial institutions. The Company also assesses the credit quality of counterparties, taking into account their financial position, past experience and other factors.

Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due.

As at June 30, 2026, the Company's financial liabilities consist of account payable and accrued liabilities.

The Company manages liquidity risk through an ongoing review of future commitments and cash balances available. Historically, the Company's main source of funding has been the issuance of shares for cash, primarily through private placements. The Company's access to financing is always uncertain. There can be no assurance of continued access to significant equity or debt funding.

The following table illustrates the contractual maturities of financial liabilities as at June 30, 2026:

Financial Instrument Maturity ($)	Carrying amount	Contractual cash flows	Less than 1 year	Between 1 and 3 years
Accounts payable and accrued liabilities	133,019	133,019	133,019	-
Total	133,019	133,019	133,019	-

Foreign exchange risk

Foreign currency risk is the risk that the fair values of future cash flows of a financial instrument will fluctuate because they are denominated in currencies that differ from the respective functional currency.

The Company operates internationally and is exposed to foreign exchange risk from the AUD and USD. Foreign exchange risk arises from transactions as well as recognized financial assets and liabilities denominated in foreign currencies.

A 10% adverse change in exchange rate would have resulted in a loss of $37,734 as at June 30, 2026.

Interest rate risk

Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company has no significant interest-bearing assets or liabilities and therefore its income and operating cash flows are substantially independent of changes in market interest rates.

(Expressed in Canadian Dollars)

15. Loss per share

The calculation of basic and diluted profit/(loss) per common share for the period ended June 30, 2026 and June 30, 2025 was calculated as follows:

Earnings per share ($)	**June 30, 2026**	**June 30, 2025**
Basic and diluted loss per share:		
Net loss	(99,868)	(11,633,085)
Average number of common shares outstanding	2,318,480	1,827,229
Loss per share – basic and diluted	(0.04)	(6.37)

The diluted weighted average number of common shares does not take into account the effects of stock options and warrants as they would be anti-dilutive for the period ended June 30, 2026 and June 30, 2025.

16. Capital management

The Company manages its cash and cash equivalents and the components of shareholders' equity as capital. The Company's objectives when managing capital are to safeguard the Company's ability to continue as a going concern in order to pursue the development of natural health business, to maintain a flexible capital structure which optimizes the cost of capital at an acceptable risk level.

The Company manages its capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust its capital structure, the Company may attempt to issue new shares, issue new debt, acquire or dispose of assets or adjust the amount of cash and short-term investments on hand.

In order to facilitate the management of its capital requirements, the Company prepares annual budgets that are updated as necessary depending on various factors, including successful capital deployment and general industry conditions. The annual and updated budgets are approved by the Board of Directors.

Management considers its approach to capital management to be appropriate given the relative size of the Company. There were no changes in the Company's approach to capital management during the year.

17. Subsequent Events

On July 17, 2026, the CSE informed GoldCoast that following an internal Listing Application review, the CSE approved the listing subject to the following conditions:

- Completion of the Amalgamation Agreement previously dated November 30, 2025 and amended on dates April 13, 2026 and July 20, 2026 as described in Listing Statement.
- Completion of any and all outstanding CSE application documentation and the payment of fees pursuant to the Policies.
- The approval is valid for maximum of six months.

On July 20, 2026, the Company entered an amendment with GoldCoast and Psyence Therapeutics Corp, to the previously announced amalgamation agreement dated November 21, 2025. The Amendment accounts for the replacing the closing date by deleting "May 31, 2026" with "July 31, 2026".

On July 27, 2026, the Company completed the previously announced business combination with GoldCoast. As part of closing, the Company completed a share consolidation of 6.9565 old shares for

(Expressed in Canadian Dollars)

1 new shares was affected. The number of shares in issue and weighted average number of shares for all periods presented have been retrospectively restated to reflect this consolidation. Pysence Therapeutics Corp. a subsidiary 100% owned by the Company amalgamated with former Goldcoast Resource Corp. and the new amalgamated corporation changed its name to 1001690554 Ontario Inc. and became a 100% owned subsidiary of the Company, while the Company. changed it's name to GoldCoast Resource Corp. and its common shares have commenced trading on the Canadian Securities Exchange ("CSE") under the ticker symbol "GCR" from August 10, 2026. As of July 27, 2026 GoldCoast Resource Corp. has the following common shares outstanding:

Shares issued to the shareholders of GoldCoast	63,513,155
New shaes issued to a consultant of Goldcoast	3,478,635
Shares issued to Psyence shareholders	2,318,480
Shares issued to Psyence RSUs	97,999
Shares issued a consultant of Psyence	400,000
Total	69,808,269

As of July 27, 2026 GoldCoast Resource Corp. has issued 4,180,563 options to the options holders of the former Goldcoast shareholders, and 18,894 options to the former options holders of the Company.